Emrosi - (40 mg ; Extended-release Capsules)

Generic Name	Minocyline Hydrochloride	Innovator	Journey medical corp
Dosage	40 mg ; Extended-release Capsules	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events